Drug Profile
203 Pb AR RMX
Alternative Names: 203 Pb-AR-RMX-15Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator AREVA Med; RadioMedix
- Developer Orano Med; RadioMedix
- Class Lead radioisotopes; Peptides; Radiopharmaceutical diagnostics
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuroendocrine tumours
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for clinical-Phase-Unknown development in Neuroendocrine-tumours(Diagnosis) in Unknown (Parenteral)
- 22 Jun 2017 Efficacy data from a clinical trial in Neuroendocrine tumours (Diagnosis) released by RadioMedix and AREVA Med
- 31 May 2017 Clinical trials in Neuroendocrine tumours (Diagnosis) (Parenteral) before May 2017